文献速递关节外科

同期口服糖皮质激素的剂量或持续时间是否影响全关节置换术后并发症风险升高

Does Dosage or Duration of Concurrent Oral Corticosteroid Influence Elevated Risk of Postoperative Complications After Total Joint Arthroplasty?
PubMed 文献 · J Arthroplasty · 2021-12-28

这项回顾性单机构研究纳入1128例初次全关节置换术(905例全髋、223例全膝),平均随访51.9±34.1个月,其中120个关节(10.6%)有慢性同期口服糖皮质激素使用。多因素分析显示美国麻醉医师协会体能状态3级是术后并发症的独立危险因素,而同期口服糖皮质激素使用不是独立危险因素;在慢性使用者中,有并发症组(n=13)与无并发症组(n=107)的剂量(P=.97)和持续时间(P=.69)均无统计学差异。结论认为糖皮质激素剂量或持续时间均不能预测全关节置换术后并发症。

要点

  • 美国麻醉医师协会体能状态3级是初次全关节置换术后并发症的独立危险因素。
  • 慢性同期口服糖皮质激素使用不是术后并发症的独立危险因素。
  • 慢性使用者中有并发症组与无并发症组的激素剂量和持续时间无统计学差异。

核心结论

  • 同期口服糖皮质激素的剂量和持续时间均不能预测初次全关节置换术后并发症。
  • 美国麻醉医师协会体能状态3级是全关节置换术后并发症的主要因素。

研究设计与样本

  • 回顾性单机构研究,纳入1128例初次全关节置换术,包括905例全髋关节置换术和223例全膝关节置换术,最低随访6个月。
  • 平均随访51.9±34.1个月(范围6至146个月),120个关节(10.6%)有慢性同期口服糖皮质激素使用。

主要发现

  • 多因素分析显示美国麻醉医师协会体能状态3级是术后并发症的独立危险因素,而同期口服糖皮质激素使用不是独立危险因素。
  • 在慢性同期口服糖皮质激素使用者中,有并发症组(n=13)与无并发症组(n=107)的剂量无统计学差异(P=.97),持续时间无统计学差异(P=.69)。
  • 口服糖皮质激素剂量和持续时间的受试者工作特征曲线下面积分别为0.482和0.549。

关键数值与推荐

  • 慢性同期口服糖皮质激素使用者中有并发症组(n=13)与无并发症组(n=107)的剂量比较P=.97,持续时间比较P=.69。
  • 口服糖皮质激素剂量的曲线下面积为0.482,持续时间的曲线下面积为0.549。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This report seeks to clarify whether the dosage and duration of preoperative concurrent corticosteroid use influence postoperative complications after primary total joint arthroplasty (TJA). METHODS: This retrospective single institutional study enrolled 1128 primary TJA cases, including 905 total hip arthroplasties and 223 total knee arthroplasties at a minimum 6 months of follow-up. Mean follow-up period was 51.9 ± 34.1 months (range 6-146). Of all joints, 120 joints (10.6%) were associated with chronic concurrent oral corticosteroid use. Multivariate analysis was performed to identify whether chronic concurrent oral corticosteroid use elevated the risk of postoperative complications including surgical site infection/periprosthetic joint infection, delayed wound healing, periprosthetic fracture, and implant loosening. For chronic concurrent oral corticosteroid user, we determined whether the dosage and duration of preoperative concurrent corticosteroid use influenced postoperative complications and have an effective threshold for postoperative complications using receiver operating characteristic curve analysis. RESULTS: The multivariate analysis revealed that American Society of Anesthesiologist Physical Status 3 was an independent risk factor for postoperative complications, while concurrent oral corticosteroid use was not an independent risk factor. When we compared joints with (n = 13) and without (n = 107) postoperative complications in chronic concurrent oral corticosteroid user, there was no statistical difference in the dosage (P = .97) and duration (P = .69) between the 2 groups. Area under the curve values for the oral corticosteroid dosages and duration were 0.482 and 0.549, respectively. CONCLUSION: This study revealed that neither dosage nor duration of concurrent oral corticosteroid use was predictive of postoperative complications after TJA. American Society of Anesthesiologist Physical Status 3 is a major factor in postoperative complications after TJA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Inoue D, Kabata T, Kajino Y, et al. Does Dosage or Duration of Concurrent Oral Corticosteroid Influence Elevated Risk of Postoperative Complications After Total Joint Arthroplasty? J Arthroplasty. 2021. PMID: 34968651. doi:10.1016/j.arth.2021.12.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。